Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016545 | 0.86 | MMP3 (0.35) | MEN1KMT2AMMP3 | |
| SCHEMBL24402987 | 0.69 | CYP1A2 (0.38) | MEN1KMT2AMMP3 | |
| SCHEMBL23772573 | 0.68 | NPC1 (0.48) | MEN1NPC1RAB9AKMT2AHTR2A | |
| SCHEMBL19977257 | 0.67 | HTR2A (0.35) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| SCHEMBL25894256 | 0.67 | MMP3 (0.34) | MMP3 | |
| SCHEMBL21284498 | 0.66 | MMP3 (0.35) | MMP3 | |
| SCHEMBL22007144 | 0.65 | HTR1A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL8483178 | 0.64 | NPC1 (0.44) | MEN1NPC1RAB9AKMT2AHTR2A | |
| SCHEMBL24023602 | 0.62 | ALDH1A1 (0.44) | MEN1KMT2A | |
| SCHEMBL23034515 | 0.62 | CHRM5 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | MEN1 3326/4885NPC1 1714/4885RAB9A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.